All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for BRISTOL-MYERS SQUIBB · biopharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $40,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 2

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 891
Bipartisan Health Care Act

Lobbying activity 5

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; international taxation.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Health Issues

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.